Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
TORONTO, April 11, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
Adding Progressive Care (RXMD) $0.04 to Watch List.
Adding to Biotech Stock Review 2022 Watch List.
Speculative, Yes. But Pay Down of $2 Million Toxic Note and...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
Institutional Analyst Newsletter. April 14, 2022.
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict
LIVE QUOTE
Unicycive (UNCY) Shoots and Scores, up 40% Today!
We're up 126% Since December, and That Ain't Bad.
Note: This isn't the end, it's just the...
Report: First Vaccines, then Antivirals. Will the Anti-Inflammatory Be the Next Success Story in...
New Report on Revive Therapeutics (RVVTF, RVV). Ushering in Advances in Anti-Inflammatory and Antioxidant Drugs, as a Tool Against Covid.
Revive Therapeutics (RVVTF) Annual Shareholder Meeting.
ANNUAL SHAREHOLDER MEETING
https://vimeo.com/752050831
Revive (RVVTF) Hits a Snag?
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
First our summary."FDA provided communication that...
Revive Therapeutics (RVVTF) Regulatory Update Archive.
April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as...
The Race to Develop Therapeutics for COVID. The Small Caps Fight for a Treatment...
The Second Wave: Biopharma Players Race to Develop Therapeutics for COVID-19 (BioSPace) December 21.
Revive Therapeutics (RVTTF), RedHill BioPharma...
Latest article
IA Initiates Analyst Coverage of Principal Solar (Press Release).
Principal Solar, Inc.Mon, March 20, 2023 at 7:30 AM EDT
Institutional Analyst, Inc....
Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.
Going Short the Market. No Long Dissertation, No Rush. Market Risk Has Appeared, With Minimal Upside, So Time To Act.
We’re Bearish, but we’re up 257% in Provention Bio (PRVB) Today.
And up 416%, from Adding it to 2022 Watch List!
Great way to wake up after a night of...
